This phase I clinical study is to investigate the safety, tolerability and pharmacokinetics/ pharmacodynamics of BTK inhibitor BGB-3111 in Chinese patients with B-cell lymphoma, by conducting in two stages, the first stage being the safety assessment of dose, and the second stage being the dose expansion.